GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » EPS without NRI

GeneThera (GeneThera) EPS without NRI : $-0.02 (TTM As of Sep. 2022)


View and export this data going back to 2000. Start your Free Trial

What is GeneThera EPS without NRI?

GeneThera's earnings per share without non-recurring items for the three months ended in Sep. 2022 was $-0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for GeneThera's EPS without NRI or its related term are showing as below:

GTHR's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

GeneThera's EPS (Diluted) for the three months ended in Sep. 2022 was $-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.02.

GeneThera's EPS (Basic) for the three months ended in Sep. 2022 was $-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.02.


GeneThera EPS without NRI Historical Data

The historical data trend for GeneThera's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera EPS without NRI Chart

GeneThera Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.11 -0.02 -0.04 -0.04

GeneThera Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 - - -

Competitive Comparison of GeneThera's EPS without NRI

For the Biotechnology subindustry, GeneThera's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneThera's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneThera's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where GeneThera's PE Ratio without NRI falls into.



GeneThera EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneThera  (OTCPK:GTHR) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


GeneThera EPS without NRI Related Terms

Thank you for viewing the detailed overview of GeneThera's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneThera (GeneThera) Business Description

Traded in Other Exchanges
N/A
Address
3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Executives
Avel Kolesnikov director 11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr 10 percent owner 632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd 10 percent owner CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner director, officer: Chief Financial Officer 728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici director, 10 percent owner, officer: Chief Executive Officer 3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry director, 10 percent owner, officer: Chief Administative Officer 11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines